CEO Chris Gibson highlighted the company's strategic focus on the Recursion Operating System 2.0, emphasizing its capability to improve efficiency in drug discovery and development. Management ...
Welcome everybody to Recursion's Earnings Call. I'm Chris Gibson, Co-Founder and CEO, and I'm excited to take you through Recursions 2024, 2025 and the time ahead. So with that we'll jump into the ...
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q1 2025 Earnings Call Transcript May 5, 2025 Recursion Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.50273 EPS, expectations ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results